The news this week that the Food and Drug Administration (FDA) approved Aduhelm to treat Alzheimer’s disease has been met with hope, but also skepticism in terms of the drug’s clinical safety and efficacy, and its cost.
Pharmaceutical Care
Management Association
505 9th Street NW, 10th Floor, Washington, DC 20004
© 2025 PCMA. All Rights Reserved.